{"filing":{"accession_number":"0001193125-26-281143","cik":"0001672688","ticker":"ABSI","company_name":"Absci Corp","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"d139233d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233d8k.htm"},"events":[{"id":13551,"run_id":12040,"accession_number":"0001193125-26-281143","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Absci entered into an underwriting agreement on June 24, 2026 to issue 13,495,277 shares of common stock at $7.41 per share, generating approximately $100 million in gross proceeds ($93.5 million net) pursuant to an effective Form S-3 shelf registration statement. The offering includes participation from strategic investors including Eli Lilly \u0026 Company and materially dilutes existing shareholders.","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10718,"accession_number":"0001193125-26-281143","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Absci entered into an underwriting agreement on June 24, 2026 to issue 13,495,277 shares of common stock at $7.41 per share, generating approximately $100 million in gross proceeds ($93.5 million net). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly states the shares are being offered pursuant to an effective shelf registration statement (Form S-3), and the press release confirms participation from strategic and financial investors including Eli Lilly \u0026 Company. This is a material capital-raising event typical of dilutive equity issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:34:50.855105+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10719,"accession_number":"0001193125-26-281143","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Absci announced the pricing of an underwritten offering of 13,495,277 shares of common stock at $7.41 per share, raising approximately $100 million in gross proceeds. This is a registered direct equity issuance that dilutes existing shareholders. The filing explicitly states \"All of the shares in the offering are to be sold by Absci,\" confirming this is a primary offering by the company itself, not a secondary sale by insiders. The material amount ($100 million) and participation from strategic investors (Eli Lilly \u0026 Company) make this a significant capital-raising event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:34:50.855105+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10718,"accession_number":"0001193125-26-281143","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Absci entered into an underwriting agreement on June 24, 2026 to issue 13,495,277 shares of common stock at $7.41 per share, generating approximately $100 million in gross proceeds ($93.5 million net). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly states the shares are being offered pursuant to an effective shelf registration statement (Form S-3), and the press release confirms participation from strategic and financial investors including Eli Lilly \u0026 Company. This is a material capital-raising event typical of dilutive equity issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:34:50.855105+00:00","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-06-24"},{"id":10719,"accession_number":"0001193125-26-281143","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Absci announced the pricing of an underwritten offering of 13,495,277 shares of common stock at $7.41 per share, raising approximately $100 million in gross proceeds. This is a registered direct equity issuance that dilutes existing shareholders. The filing explicitly states \"All of the shares in the offering are to be sold by Absci,\" confirming this is a primary offering by the company itself, not a secondary sale by insiders. The material amount ($100 million) and participation from strategic investors (Eli Lilly \u0026 Company) make this a significant capital-raising event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:34:50.855105+00:00","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-06-24"}]}